<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01784523</url>
  </required_header>
  <id_info>
    <org_study_id>2014-253</org_study_id>
    <nct_id>NCT01784523</nct_id>
    <nct_alias>NCT02635126</nct_alias>
  </id_info>
  <brief_title>Hydroxychloroquine for the First Thrombosis Prevention in Antiphospholipid Antibody Positive Patients</brief_title>
  <official_title>A Prospective Randomized Controlled Trial of Hydroxychloroquine in the Primary Thrombosis Prophylaxis of aPL Positive But Thrombosis-free Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital for Special Surgery, New York</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AntiPhospholipid Syndrome Alliance For Clinical Trials and InternatiOnal Networking</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The New York Community Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital for Special Surgery, New York</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this multi-center international study, our aim is to determine the effectiveness of HCQ&#xD;
      for primary thrombosis prophylaxis in persistently aPL-positive but thrombosis-free patients&#xD;
      without systemic autoimmune diseases.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Randomized to receive HCQ or no treatment in addition to their standard regimen. 11 study&#xD;
      visits and 10 phone visits over 5 years.&#xD;
&#xD;
      This study was terminated at 2 years due to low recruitment rate exacerbated by manufacturing&#xD;
      shortage and price increase of hydroxychloroquine.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    low recruitment rate exacerbated by manufacturing shortage and price increase of&#xD;
    hydroxychloroquine.&#xD;
  </why_stopped>
  <start_date>February 2013</start_date>
  <completion_date type="Actual">September 30, 2015</completion_date>
  <primary_completion_date type="Actual">September 30, 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With an Acute Thrombosis Event</measure>
    <time_frame>2 years</time_frame>
    <description>To determine the efficacy of Hydroxychloroquine in the primary thrombosis prevention of persistently aPL-positive but thrombosis free patients with no other systemic autoimmune diseases over the five year study period.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Antiphospholipid Syndrome</condition>
  <arm_group>
    <arm_group_label>Standard treatment</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>patients randomized to standard treatment will not receive hydroxychloroquine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hydroxychloroquine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be randomized to receive standard of care or standard of care + hydroxychloroquine. Dose will be weight-adjusted: 200 mg daily for patients weighing &lt;60kg; and 400 mg daily (200 mg twice a day)for patients weighing &gt;60kg.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydroxychloroquine</intervention_name>
    <arm_group_label>Hydroxychloroquine</arm_group_label>
    <other_name>plaquenil</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Persistent(at least 12 weeks apart)aPL-positivity within 12 months prior to the&#xD;
             screening defined as:&#xD;
&#xD;
               -  aCL IgG/M (&gt;40U,medium-to-high titer,and/or greater than the 99th&#xD;
                  percentile)and/or&#xD;
&#xD;
               -  aÎ²2GPI IgG/M(&gt;40U, medium-to-high titer, and/or greater than the 99th&#xD;
                  percentile)and/or&#xD;
&#xD;
               -  Positive LA test based on the International Society of Thrombosis &amp; Haematosis&#xD;
                  Recommendations&#xD;
&#xD;
        Selected Exclusion Criteria:&#xD;
&#xD;
          -  History of thrombosis (arterial, venous, and/or biopsy proven microthrombosis&#xD;
&#xD;
          -  History of Transient Ischemic Attack Confirmed by a Neurologist&#xD;
&#xD;
          -  SLE Diagnosis based on the ACR Classification Criteria &gt; 4/11&#xD;
&#xD;
          -  Other Systemic Autoimmune Diseases diagnosed based on ACR Classification Criteria&#xD;
&#xD;
          -  Current Hydroxychloroquine or another antimalarial treatment (-3 months)&#xD;
&#xD;
          -  Current warfarin treatment (-3 months)&#xD;
&#xD;
          -  Current heparin therapy( -3 months)&#xD;
&#xD;
          -  Current pregnancy&#xD;
&#xD;
          -  History of Hydroxychloroquine eye toxicity&#xD;
&#xD;
          -  History of Hydroxychloroquine allergy&#xD;
&#xD;
          -  Known glucose-6-phosphate dehydrogenase deficiency&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Doruk Erkan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital for Special Surgery, New York</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital for Special Surgery</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.apsaction.org</url>
    <description>APS ACTION</description>
  </link>
  <reference>
    <citation>Erkan D, Lockshin MD; APS ACTION members. APS ACTION--AntiPhospholipid Syndrome Alliance For Clinical Trials and InternatiOnal Networking. Lupus. 2012 Jun;21(7):695-8. doi: 10.1177/0961203312437810.</citation>
    <PMID>22635205</PMID>
  </reference>
  <reference>
    <citation>Erkan D, Derksen R, Levy R, Machin S, Ortel T, Pierangeli S, Roubey R, Lockshin M. Antiphospholipid Syndrome Clinical Research Task Force report. Lupus. 2011 Feb;20(2):219-24. doi: 10.1177/0961203310395053.</citation>
    <PMID>21303838</PMID>
  </reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>February 3, 2013</study_first_submitted>
  <study_first_submitted_qc>February 3, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 6, 2013</study_first_posted>
  <results_first_submitted>March 4, 2019</results_first_submitted>
  <results_first_submitted_qc>April 9, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">May 4, 2021</results_first_posted>
  <last_update_submitted>August 18, 2021</last_update_submitted>
  <last_update_submitted_qc>August 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>antiphospholipid autoantibodies</keyword>
  <keyword>antiphospholipid positive</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Antiphospholipid Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydroxychloroquine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Standard Treatment</title>
          <description>patients randomized to standard treatment will not receive hydroxychloroquine.</description>
        </group>
        <group group_id="P2">
          <title>Hydroxychloroquine</title>
          <description>Patients will be randomized to receive standard of care or standard of care + hydroxychloroquine. Dose will be weight-adjusted: 200 mg daily for patients weighing &lt;60kg; and 400 mg daily (200 mg twice a day)for patients weighing &gt;60kg.&#xD;
Hydroxychloroquine</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Study closed early</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Standard Treatment</title>
          <description>patients randomized to standard treatment will not receive hydroxychloroquine.</description>
        </group>
        <group group_id="B2">
          <title>Hydroxychloroquine</title>
          <description>Patients will be randomized to receive standard of care or standard of care + hydroxychloroquine. Dose will be weight-adjusted: 200 mg daily for patients weighing &lt;60kg; and 400 mg daily (200 mg twice a day)for patients weighing &gt;60kg.&#xD;
Hydroxychloroquine</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
            <count group_id="B2" value="4"/>
            <count group_id="B3" value="11"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44" spread="8.98"/>
                    <measurement group_id="B2" value="45.75" spread="7.89"/>
                    <measurement group_id="B3" value="44.64" spread="8.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With an Acute Thrombosis Event</title>
        <description>To determine the efficacy of Hydroxychloroquine in the primary thrombosis prevention of persistently aPL-positive but thrombosis free patients with no other systemic autoimmune diseases over the five year study period.</description>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Standard Treatment</title>
            <description>patients randomized to standard treatment will not receive hydroxychloroquine.</description>
          </group>
          <group group_id="O2">
            <title>Hydroxychloroquine</title>
            <description>Patients will be randomized to receive standard of care or standard of care + hydroxychloroquine. Dose will be weight-adjusted: 200 mg daily for patients weighing &lt;60kg; and 400 mg daily (200 mg twice a day)for patients weighing &gt;60kg.&#xD;
Hydroxychloroquine</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With an Acute Thrombosis Event</title>
          <description>To determine the efficacy of Hydroxychloroquine in the primary thrombosis prevention of persistently aPL-positive but thrombosis free patients with no other systemic autoimmune diseases over the five year study period.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Standard Treatment</title>
          <description>patients randomized to standard treatment will not receive hydroxychloroquine.</description>
        </group>
        <group group_id="E2">
          <title>Hydroxychloroquine</title>
          <description>Patients will be randomized to receive standard of care or standard of care + hydroxychloroquine. Dose will be weight-adjusted: 200 mg daily for patients weighing &lt;60kg; and 400 mg daily (200 mg twice a day)for patients weighing &gt;60kg.&#xD;
Hydroxychloroquine</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Doruk Erkan, MD</name_or_title>
      <organization>Hospital for Special Surgery</organization>
      <phone>212 774-2291</phone>
      <email>erkand@hss.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

